Multiple Myeloma Coverage from Every Angle

Natalie S. Callander, MD, on Multiple Myeloma: Cost Effectiveness of Drugs Used to Treat Relapsed/Refractory Disease

Posted: Wednesday, September 6, 2017

Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses the cost effectiveness of carfilzomib, ixazomib, elotuzumab, daratumumab, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma, an issue critically important to patients, providers, and NCCN panel members.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.